Evaluation of selective cyclooxygenase-2 inhibitor-induced small bowel injury: Randomized cross-over study compared with loxoprofen in healthy subjects

Digestive Endoscopy

Volumn 25, Issue 3, 2013, Pages 288-294

  Mizukami, Kazuhiro ^a   Murakami, Kazunari ^a   Yamauchi, Mika ^a   Matsunari, Osamu ^a   Ogawa, Ryo ^a   Nakagawa, Yoshifumi ^a   Okimoto, Tadayoshi ^a   Kodama, Masaaki ^a   Fujioka, Toshio ^a  

^a OITA UNIVERSITY   (Japan)

Author keywords

capsule endoscopy; celecoxib; loxoprofen; non steroidal anti inflammatory drug; small bowel injury

Indexed keywords

CELECOXIB; FAMOTIDINE; LOXOPROFEN;

ARTICLE; CAPSULE ENDOSCOPY; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG SAFETY; ERYTHEMA; HUMAN; HUMAN EXPERIMENT; INCIDENCE; MALE; NORMAL HUMAN; PEPTIC ULCER; RANDOMIZED CONTROLLED TRIAL; SMALL INTESTINE DISEASE; SMALL INTESTINE MUCOSA INJURY;

ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CAPSULE ENDOSCOPY; CROSS-OVER STUDIES; CYCLOOXYGENASE 2 INHIBITORS; HUMANS; INTESTINE, SMALL; JAPAN; MALE; MIDDLE AGED; PHENYLPROPIONATES; PYRAZOLES; SULFONAMIDES;

EID: 84876693272     PISSN: 09155635     EISSN: 14431661     Source Type: Journal    
DOI: 10.1111/j.1443-1661.2012.01379.x     Document Type: Article

References (33)

1. Japanese Society of Gastroenterology (eds). Guidelines on Management of Peptic Ulcers. Tokyo: Nankodo, 2009.
2. Graham DY, Agrawal NM, Roth SH, (eds). Prevention of NSAIDs-induced gastric ulcer with misoprostol: multicentre, double-blind, placebo-controlled trial. Lancet 1988; 2: 1277-1280.
3. Taha AS, Hudson N, Hawkey CJ, et al. Famotidine in the prevention of gastric and duodenal ulcers caused by non-steroidal antiinflammatory drugs. N. Engl. J. Med. 1996; 334: 1435-1439.
4. Hawkey CJ, Karrasch JA, Szczepanski L, et al. Omeprazole compared with misoprostol for ulcers associated with non-steroidal antiinflammatory drugs. Omeprazole versus Misoprostol for NSAIDs-induced Ulcer Management (OMNIUM) Study Group. N. Engl. J. Med. 1998; 338: 727-734.
5. Wolfe MM, Lichtenstein DR, Singh G,. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N. Engl. J. Med. 1999; 340: 1888-1899.
6. Hooper L, Brown TJ, Elliott R, Payne K, Roberts C, Symmons D,. The effectiveness of five strategies for the prevention of gastrointestinal toxicity induced by non-steroidal anti-inflammatory drugs: systematic review. BMJ 2004; 329: 948.
7. Iddan G, Meron G, Glukhovsky A, Swain P,. Wireless capsule endoscopy. Nature 2000; 405: 417.
8. Yamamoto H, Sekine Y, Sato Y, et al. Total enteroscopy with a nonsurgical steerable double-balloon method. Gastrointest. Endosc. 2001; 53: 216-220.
9. Graham DY, Opekun AR, Willingham FF, Qureshi WA,. Visible small-intestinal mucosal injury in chronic NSAID users. Clin. Gastroenterol. Hepatol. 2005; 3: 55-59.
10. Maiden L, Thjodleifsson B, Theodors A, Gonzalez J, Bjarnason I,. A quantitative analysis of NSAID-induced small bowel pathology by capsule enteroscopy. Gastroenterology 2005; 128: 1172-1178.
11. Sugimori S, Watanabe T, Tabuchi M, et al. Evaluation of small bowel injury in patients with rheumatoid arthritis by capsule endoscopy: effects of anti-rheumatoid arthritis drugs. Digestion 2008; 78: 208-213.
12. Fujimori S, Seo T, Gudis K, et al. Prevention of nonsteroidal anti-inflammatory drug-induced small-intestinal injury by prostaglandin: a pilot randomized controlled trial evaluated by capsule endoscopy. Gastrointest. Endosc. 2009; 69: 1339-1346.
13. Niwa Y, Nakamura M, Ohmiya N, et al. Efficacy of rebamipide for diclofenac-induced small-intestinal mucosal injuries in healthy subjects: a prospective, randomized, double-blinded, placebo-controlled, cross-over study. J. Gastroenterol. 2008; 43: 270-276.
14. Fujimori S, Takahashi Y, Gudis K, et al. Rebamipide has the potential to reduce the intensity of NSAID-induced small intestinal injury: a double-blind, randomized, controlled trial evaluated by capsule endoscopy. J. Gastroenterol. 2011; 46: 57-64.
15. Emery P, Zeidler H, Kvien TK, et al. Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomised double-blind comparison. Lancet 1999; 354: 2106-2111.
16. Singh G, Fort JG, Goldstein JL, et al. SUCCESS-I Investigators. Celecoxib versus naproxen and diclofenac in osteoarthritis Patients: SUCCESS-I Study. Am. J. Med. 2006; 119: 255-266.
17. Simon LS, Weaver AL, Graham DY, et al. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial. JAMA 1999; 282: 1921-1928.
18. Sakamoto C, Soen S,. Efficacy and safety of the selective cyclooxygenase-2 inhibitor celecoxib in the treatment of rheumatoid arthritis and osteoarthritis in Japan. Digestion 2011; 83: 108-123.
19. Goldstein JL, Correa P, Zhao WW, et al. Reduced incidence of gastroduodenal ulcers with celecoxib, a novel cyclooxygenase-2 inhibitor, compared to naproxen in patients with arthritis. Am. J. Gastroenterol. 2001; 96: 1019-1027.
20. Hawkey CJ, Svoboda P, Fiedorowicz-Fabrycy IF, et al. Gastroduodenal safety and tolerability of lumiracoxib compared with Ibuprofen and celecoxib in patients with osteoarthritis. J. Rheumatol. 2004; 31: 1804-1810.
21. Astellas Pharma Inc,. Celecox Package Insert (4th edition). Tokyo, 2011.
22. Whittle BJ,. Mechanisms underlying intestinal injury induced by anti-inflammatory COX inhibitors. Eur. J. Pharmacol. 2004; 500: 427-439.
23. Bjarnason I, Hayllar J, Smethurst P, Price A, Gumpel MJ,. Metronidazole reduces intestinal inflammation and blood loss in non-steroidal anti-inflammatory drug induced enteropathy. Gut 1992; 33: 1204-1208.
24. Niwa Y, Nakamura M, Miyahara R, et al. Geranylgeranylacetone protects against diclofenac-induced gastric and small intestinal mucosal injuries in healthy subjects: a prospective randomized placebo-controlled double-blind cross-over study. Digestion 2009; 80: 260-266.
25. Yamao J, Kikuchi E, Matsumoto M, et al. Assessing the efficacy of famotidine and rebamipide in the treatment of gastric mucosal lesions in patients receiving long-term NSAID therapy (FORCE-famotidine or rebamipide in comparison by endoscopy). J. Gastroenterol. 2006; 41: 1178-1185.
26. Needleman P, Isakson PC,. The discovery and function of COX-2. J. Rheumatol. 1997; 24: 6-8.
27. Kurumbail RG, Stevens AM, Gierse JK, et al. Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents. Nature 1996; 384: 644-648.
28. Gierse JK, Koboldt CM, Walker MC, Seibert K, Isakson PC,. Kinetic basis for selective inhibition of cyclo-oxygenases. Biochem. J. 1999; 339: 607-614.
29. Somasundaram S, Rafi S, Hayllar J, et al. Mitochondrial damage: a possible mechanism of the 'topical' phase of NSAID induced injury to the rat intestine. Gut 1997; 41: 344-353.
30. Somasundaram S, Sigthorsson G, Simpson RJ, et al. Uncoupling of intestinal mitochondrial oxidative phosphorylation and inhibition of cyclooxygenase are required for the development of NSAID-enteropathy in the rat. Aliment. Pharmacol. Ther. 2000; 14: 639-650.
31. Bjarnason I, Williams P, So A, et al. Intestinal permeability and inflammation in rheumatoid arthritis: effects of non-steroidal anti-inflammatory drugs. Lancet 1984; 2: 1171-1174.
32. Goldstein JL, Eisen GM, Lewis B, Gralnek IM, Zlotnick S, Fort JG,. Investigators. Video capsule endoscopy to prospectively assess small bowel injury with celecoxib, naproxen plus omeprazole, and placebo. Clin. Gastroenterol. Hepatol. 2005; 3: 133-141.
33. Goldstein JL, Eisen GM, Lewis B, et al. Small bowel mucosal injury is reduced in healthy subjects treated with celecoxib compared with ibuprofen plus omeprazole, as assessed by video capsule endoscopy. Aliment. Pharmacol. Ther. 2007; 25: 1211-1222.